Indian pharmaceutical company Hetero Drugs has received emergency use approval from the country's health authorities to make a generic version of Swiss healthcare company Roche Holding AG's (SWX:ROG.S) COVID-19 drug, tocilizumab, Reuters news agency reported on Monday.
Hetero expects to make tocilizumab available in India by the end of the month under the brand name Tocira.
It will reportedly be made by Hetero's unit at its Hyderabad facility.
Roche's arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval